Myocardial ischemia reperfusion injury
Conditions
Interventions
Electroacupuncture group:On the basis of receiving health education and essential drug treatment, electroacupuncture was used. For routine disinfection of Neiguan point and the skin nearby, 0.25*20mm
The needle was retained for 30min each time, once every other day, three times a week, a total of 12 times of treatment.
Shame group:On the basis of receiving health education and essential drug treatment, electroacupuncture was used. For the routine disinfection of Neiguan point and the skin nearby, 0.25*20mm filiform
Press needle group:On the basis of receiving health education and essential drug treatment, press needle therapy was used. The Neiguan point and the nearby skin were disinfected routinely, and the pre
2-3 times a week, 2-3 days each time, for a total of 4 weeks of intervention.
Control group:Only received health education and conventional drug treatment, without acupuncture treatm
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80 years old, gender unlimited; 2. Patients with coronary heart disease < 3 months after percutaneous coronary stent implantation and treated with conventional western medicine; 3.Those who voluntarily take the test and sign the informed consent.
Exclusion criteria
Exclusion criteria: cTnI > 0.4 µ g/L; 2. Taking psychotropic drugs; 3. There has been a stroke (cerebral hemorrhage, subarachnoid hemorrhage, cerebral thrombosis, cerebral embolism and stroke of unknown type) within the last 6 months; 4. Combined with poorly controlled hypertension (>=180/100 MMHG) or hypotension (< 90/60 MMHG); 5. Patients with recurrent malignant arrhythmias (ventricular tachycardia, rapid atrial fibrillation, atrial flutter, type II ° II or above atrioventricular block, complete bundle branch block) in recent times or those with arrhythmias and cardiac pacemakers; 6. Combined with severe liver and kidney dysfunction (creatinine clearance rate <=40ml/min, serum transaminase =2× upper limit of clinical reference value), other serious primary diseases that affect lifespan, tumors or severe mental disorders; 7. Women who are pregnant, planning to become pregnant or breastfeeding; 8. Known bleeding tendency or hemorrhagic disease, or uncontrollable coagulation mechanism disorder, or active bleeding and invasive examination and treatment procedures within 2 weeks, or severe trauma or major surgery history within 12 weeks; 9. Those who are currently participating in other clinical trials; 10. Current or past history of drug abuse or drug use; 11. Those who suffer from dementia or severe mental disorders that prevent them from understanding or expressing informed consent; 12. Individuals with drug or alcohol dependence, or other circumstances that the researcher deems unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of angina symptoms;Primary composite endpoint (cardiac death, nonfatal myocardial infarction, unplanned revascularization); | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual analogue scale (VAS);Observation of ST-T Holter;Seattle Angina Questionnaire (SAQ);Self rating Anxiety Scale (SAS);Self rating Depression Scale (SDS);Computational analysis of RNA-Seq data;Computational analysis of ChIP-Seq data; | — |
Countries
China
Contacts
Public ContactYang Han
West China Hospital of Sichuan University
Outcome results
None listed